<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876197</url>
  </required_header>
  <id_info>
    <org_study_id>CVB2019-1</org_study_id>
    <secondary_id>2014-004349-29</secondary_id>
    <nct_id>NCT03876197</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells for Radiation-induced Xerostomia</brief_title>
  <official_title>Follow-up Study of Safety and Efficacy in Subjects Who Participated in the Study of Intraglandular Mesenchymal Stem Cells in Patients With Radiation-induced Hyposalivation and Xerostomia (MESRIX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in&#xD;
      subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a LTFU study to assess the long-term and late effects of treatment with MSCs or&#xD;
      placebo given ultrasound-guided into the submandibular glands in subjects participating in&#xD;
      the MESRIX trial. Study participants from the MESRIX trial will be invited for a clinical&#xD;
      visit. The visit will include medical history, an ENT examination; measurements of the saliva&#xD;
      production by sialometry, a Magnetic resonance imaging scan (MRI) and obtaining data on the&#xD;
      patient-reported outcome with Xerostomia Questionnaire (XQ) and Visual-Analogue-Symptomatic&#xD;
      scale (VAS). Subjects, who are not able or willing to attend a clinical visit, will be&#xD;
      encouraged to fill out the Questionnaires online or on paper. If a study participant has&#xD;
      deceased, information of the cause of death will be investigated in The Danish Register of&#xD;
      Causes of Death&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Long-term follow-up of Randomized controlled trial MESRIX</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Serious Adverse Events (SAEs) and new chronic diseases</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>SAEs according to the ICH-GCP definition and new chronic diseases. For patients not attending the planned hospital visit consider searching The National Patient Register will be searched for registered SAEs. Number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Overall survival is defined as the time from the intraglandular dose of the investigational product (MSCs or placebo) to the date of death or the date the subject is last known to be alive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse of oropharyngeal cancer</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Number of participants with relapse will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New malignancies</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Number of subjects who have new malignancies will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Zoonotic Diseases</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Number of subjects diagnosed Zoonotic Diseases will be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome measures-Health-related quality of life (HRQoL</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Xerostomia Questionnaire (XQ) ( Median item scores for each of the 8 questions will be reported (score range 0-10) and the XQ summary/composite score (0-100))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Radiation Toxicity</condition>
  <condition>Xerostomia Due to Radiotherapy</condition>
  <condition>Dry Mouth</condition>
  <condition>Hyposalivation</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <condition>Mesenchymal Stromal Cells</condition>
  <condition>Long Term Adverse Effects</condition>
  <arm_group>
    <arm_group_label>Autologous Adipose-derived mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose-derived mesenchymal stem/stromal cells</intervention_name>
    <description>Autologous adipose-derived mesenchymal stem/stromal cells</description>
    <arm_group_label>Autologous Adipose-derived mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Assessment of safety and treatment efficacy in subjects who were enrolled in the&#xD;
             MESRIX Phase I/II clinical trial&#xD;
&#xD;
          2. Subjects who were treated with either autologous mesenchymal stem cells or placebo&#xD;
&#xD;
          3. Subjects who voluntarily decided to participate and signed the consent form after&#xD;
             receiving explanations on the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Subjects who were not enrolled in the MESRIX trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Lynggaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Otolaryngology, University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Charlotte Lynggaard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Xerostomia Due to Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
    <mesh_term>Long Term Adverse Effects</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

